A PYMNTS Company

Looking for Sense in the Italian Antitrust Authority Decision in the Pfizer Xalatan Case

BY | July 27, 2012

Daniela Ampollini, Jul 27, 2012 The January 2012 decision of the Italian Antitrust Authority (“IAA”) in the Pfizer case, involving Pfizer’s actions to counter the marketing of generic versions of its…

Daniela Ampollini, Jul 27, 2012

The January 2012 decision of the Italian Antitrust Authority (“IAA”) in the Pfizer case, involving Pfizer’s actions to counter the marketing of generic versions of its product Xalatan, has given rise to a debate which has hardly appeased. Many commentators have already provided their impression from a competition law perspective. I, a patent lawyer, will try to provide mine, starting from the meaning and function of the patent law categories inv

...
THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 44.200.77.92

Please verify email or join us to access premium content!